Bulletin du cancer最新文献_第6页

Discrepancy in withdrawn accelerated approvals of anticancer agents in the United States (US) and Europe: Approval does not mean access. 美国和欧洲在撤回抗癌药加速审批方面存在差异：批准并不意味着使用。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-11-08 DOI: 10.1016/j.bulcan.2024.09.006

Dominique Levêque

引用次数: 0

[Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer]. [曲氟尿苷-替吡嘧啶加贝伐单抗治疗难治性转移性结直肠癌]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1016/j.bulcan.2024.08.009

Clara Tasseau, Claire Gallois

引用次数: 0

[Amivantamab with chemotherapy - Non-small cell lung cancer with EGFR exon 20 insertions]. [阿米万他单抗与化疗--表皮生长因子受体外显子 20 插入的非小细胞肺癌]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-10-07 DOI: 10.1016/j.bulcan.2024.08.014

Noémie Drappier, Thomas Pierret

引用次数: 0

[Fruquintinib for patients with metastatic colorectal cancer previously treated with standard treatments]. [曾接受标准疗法治疗的转移性结直肠癌患者的福罗替尼]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-10-24 DOI: 10.1016/j.bulcan.2024.08.018

Chloé Chatelet, Stanislas Quesada

引用次数: 0

[Onco-palliative ecotone: More than "supportive care", a frontier rich in diversity for holistic medicine and rational humanism]. [肿瘤姑息生态区：不仅仅是 "支持性护理"，整体医学和理性人文主义的丰富多样性前沿]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-11-07 DOI: 10.1016/j.bulcan.2024.10.002

Élise Chartier, Dauphine D'Andigné, Marie-Hélène Ducoin, Pénélope Fay, Adrien Calmus, Armel Reffet, Jean Michel Peloni, Maguelonne De La Hautière, François Blot, Julie Pouget

引用次数: 0

Efficiency and safety of androgen deprivation therapy combined with stereotactic body radiation therapy for localized prostate cancer: A Moroccan experience. 雄激素剥夺疗法联合立体定向体放射治疗局部前列腺癌的效率和安全性：摩洛哥的经验。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1016/j.bulcan.2024.10.004

Fadila Kouhen, Malak Chahid, Hanae El Gouache, Othmane Kaanouch, Abdeljalil Heddat, Younes Houry, Abdelhak Maghous

{"title":"Efficiency and safety of androgen deprivation therapy combined with stereotactic body radiation therapy for localized prostate cancer: A Moroccan experience.","authors":"Fadila Kouhen, Malak Chahid, Hanae El Gouache, Othmane Kaanouch, Abdeljalil Heddat, Younes Houry, Abdelhak Maghous","doi":"10.1016/j.bulcan.2024.10.004","DOIUrl":"10.1016/j.bulcan.2024.10.004","url":null,"abstract":"Purpose: This study aims to evaluate the efficacy and safety of combining androgen deprivation therapy (ADT) with stereotactic body radiation therapy (SBRT) in the treatment of localized prostate cancer.Methods: A retrospective analysis was conducted on 30 patients treated with SBRT for localized prostate cancer at Cheikh Khalifa Hospital between 2017 and 2022. All patients presented with intermediate prognostic risk prostate cancer, as classified by the D'Amico criteria. Each patient received a total dose of 36.25Gy in five fractions using the TrueBeam STX system, along with six months of ADT. Patient outcomes were assessed based on relapse-free survival, biochemical recurrence, overall survival, and adverse effects, including gastrointestinal (GI) and genitourinary (GU) toxicities. Quality of life was evaluated using the EPIC-26 questionnaire.Results: Over a median follow-up period of 33months, the relapse-free survival rate was 96.7%, with a biochemical recurrence rate of 3.3%. The overall survival rate at four years was 100%. Acute GI toxicities were minimal and transient, while GU toxicities were primarily grades 1 and 2, with no grade 3 or higher events reported. Erectile dysfunction was noted in 87% of patients. Quality of life assessments indicated low levels of urinary and bowel side effects but moderate impact on sexual function.Conclusion: These findings suggest that the combination of ADT with SBRT approach offers favorable relapse-free and overall survival rates with manageable toxicity profiles. Further long-term studies are needed to confirm these results and better understand the impact on patient quality of life.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"1102-1110"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Preventing the risks of interaction between cancer treatments and complementary care strategies]. [预防癌症治疗与辅助治疗策略之间相互作用的风险]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-11-15 DOI: 10.1016/j.bulcan.2024.10.008

Grégory Ninot, Dominique Granier, Caroline Perrier, Fanny Leenhardt, Jean-Luc Faillie, Pierre Senesse

引用次数: 0

[Claudine 18.2: A new therapeutic target in digestive cancers]. [Claudine 18.2：消化系统癌症的新治疗靶点]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-11-07 DOI: 10.1016/j.bulcan.2024.10.006

Laure Blondet, Baptiste Cervantes, Florence Renaud, Romain Cohen, Thierry André, Thomas Samaille

{"title":"[Claudine 18.2: A new therapeutic target in digestive cancers].","authors":"Laure Blondet, Baptiste Cervantes, Florence Renaud, Romain Cohen, Thierry André, Thomas Samaille","doi":"10.1016/j.bulcan.2024.10.006","DOIUrl":"10.1016/j.bulcan.2024.10.006","url":null,"abstract":"Therapies targeting HER2 and immune checkpoint inhibitors have improved survival in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma, but the prognosis associated with these cancers remains poor. Claudin 18.2 is a tight junction protein expressed in the oeso-gastric mucosa. Some gastric and gastro-oesophageal junction adenocarcinoma overexpress this protein, as well as some pancreatic, ovarian and pulmonary cancers. In pathological context, its epitope may be exposed at the surface of cells and therefore makes it an interesting therapeutic target. Zolbetuximab, a monoclonal antibody targeting claudin 18.2, showed a survival benefit in first line metastatic treatment in patients with claudin 18.2 positive gastric and gastro-oesophageal junction adénocarcinoma, in two phase III studies. CAR T-cells specifically targeting this protein have also shown promising efficacy from the second line of treatment. Considering the probable impact of the expression status of claudin 18.2 in future treatment algorithms, this review aims to present the pathophysiology underlying the targeting of claudin 18.2, summarize state of the art results of anti-claudin 18.2 therapies and discuss future challenges for the management of patients with claudin 18.2 positive gastric and gastro-oesophageal junction adenocarcinoma.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"1133-1141"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Cardiovascular adverse effects of Bruton tyrosine kinase inhibitors: Pathophysiological mechanisms, screening, and management]. [布鲁顿酪氨酸激酶抑制剂对心血管的不良影响：病理生理机制、筛查和管理]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-11-07 DOI: 10.1016/j.bulcan.2024.09.007

Jennifer Cautela, Carolyne Croizier, Luca Inchiappa, Trecy Goncalves, Nicolas Stocker, Emmanuelle Tchernonog

{"title":"[Cardiovascular adverse effects of Bruton tyrosine kinase inhibitors: Pathophysiological mechanisms, screening, and management].","authors":"Jennifer Cautela, Carolyne Croizier, Luca Inchiappa, Trecy Goncalves, Nicolas Stocker, Emmanuelle Tchernonog","doi":"10.1016/j.bulcan.2024.09.007","DOIUrl":"10.1016/j.bulcan.2024.09.007","url":null,"abstract":"The covalent Bruton tyrosine kinase inhibitors (iBTKs) have profoundly transformed the management of B-cell lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). These targeted therapies, with ibrutinib as the pioneer, have paved the way for significant improvement in the prognosis of many patients. With second-generation iBTKs such as acalabrutinib and zanubrutinib, the therapeutic landscape has expanded, offering potential new options for patients with CLL. This review focuses on the cardiovascular adverse effects associated with these treatments. It delves into the underlying pathophysiological mechanisms of these effects, highlighting the complex interactions between these molecules and the cardiovascular system. Additionally, it examines the frequency of adverse effects according to the type of iBTK, drawing on data from clinical trials and real-world clinical practice. Finally, the importance of close cardio-oncological monitoring is emphasized, with essential collaboration between hematologists and cardiologists. Strategies for screening and managing cardiovascular adverse effects are also discussed, emphasizing the need for a proactive approach in managing these complications. Experts propose a pragmatic follow-up of these patients, through a central illustration and a figure adapted from European cardio-oncology guidelines, to simplify hematologists' practice.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"1142-1153"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Implementation and evaluation satisfaction of the city-hospital link in a medical oncology department of a university hospital: An observational prospective study]. [一家大学医院肿瘤内科的市院联系实施情况和评估满意度：前瞻性观察研究]。

Bulletin du cancer Pub Date : 2024-12-01 Epub Date: 2024-11-12 DOI: 10.1016/j.bulcan.2024.10.005

Kylian Masse, Jean-François Huon, Pierre Chapron, Pierre Nizet

{"title":"[Implementation and evaluation satisfaction of the city-hospital link in a medical oncology department of a university hospital: An observational prospective study].","authors":"Kylian Masse, Jean-François Huon, Pierre Chapron, Pierre Nizet","doi":"10.1016/j.bulcan.2024.10.005","DOIUrl":"10.1016/j.bulcan.2024.10.005","url":null,"abstract":"Introduction: The care of cancer patients involves a large number of healthcare professionals. Communication at the transition points between healthcare establishments and primary care providers needs to be improved. The aim of this study is to evaluate the satisfaction of community pharmacists regarding the transmission of the discharge letter when their patient is discharged from an oncology ward.Methods: The patients included were those discharged from hospital with one or more changes in treatment during their hospitalization in the Multidisciplinary Medial Oncology Unit of the University Hospital Center of Nantes and who returned home. From April 1, 2023 to December 1, 2023, a seventeen-question questionnaire was e-mailed to the community pharmacists of the patients included in the study.Results: Forty-eight patients benefited from medication reconciliation at discharge. Thirty-eight pharmacists (79%) responded to the questionnaire. Of the 35 pharmacists that indicated they had received the discharge letter, 32 found it useful (42.9%) or very useful (48.6%), and were in favor of receiving it via e-mail (97.2%). For 94.3% of pharmacists, the document provided sufficient information.Discussion: Transmitting the discharge letter to dispensing pharmacists would seem to be an interesting option for fostering the city-hospital link. Its presentation and content seemed to meet the expectations of community pharmacists. The pharmacists felt that the continuity of care was important for ensuring their patient's care, but that it required improvement.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"1122-1132"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0